Skip to main content
OpenTrials
Completed

NCT Number: NCT05416034

Exoskeleton Impact on the Quality of Life on Patients With Spinal Muscular Atrophy

The purpose of this study is to evaluate the impact of the use of a pediatric exoskeleton on the quality of life of children, specifically in the psychological and care dimensions. Other objectives are to evaluate changes at the physical and functional level.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients between 4 and 9 years old
  • Patients with a confirmed diagnostic of Spinal Muscular Atrophy Type II

Exclusion criteria

  • Weight over 40 Kg
  • Hip-knee distance less than 22 cm or greater than 38cm
  • Knee-ankle distance less than 21 cm or greater than 37cm
  • Distance between trochanters less than 24 cm or greater than 40cm
  • Joint range limit greater than 20º

Treatment and study plan

Use of the ATLAS 2025 exoskeleton at home

Device

Each participant will use the ATLAS 2025 exoskeleton at their homes, 5 days a week during a period of two months, for walking with the device and performing motor activities in 60 minutes duration sessions..

Primary outcomes

  1. Phenomenological Interviews

    Time frame: 2 months

    Assess the psychological impact of the experience on both children and the main care giver through phenomenological interviews.

    The phenomenological interview was an open interview evaluating how the participants lived the experience of using an exoskeleton at home

  2. Care impact

    Time frame: 2 months

    To evaluate the impact of the experience in self-care of children by conducting nursing evaluations based on the Self-Care Theory developed by Dorothea Orem, before, during the use of the exoskeleton and at the end. To collect the data needed to complete the nursing assessment, structured nursing interviews were conducted with each child's primary caregiver.

    No scales are used to assess the care impact. A positive care impact will be considered if by using the exoskeleton any children or parents have an increase in any self-care agency.

    A negative care impact will be considered if by using the exoskeleton any self-care demand can not be satisfied by the self-care agency of any of the children or parents.

  3. Participant observation

    Time frame: 2 months

    Assess the psychological impact of the experience on both children and the main care giver through participant observation.

    Participant observation was performed during exoskeleton use sessions in the children's homes. Data was taken by field notes of everything that happened during the session.

Secondary outcomes

  1. Upper limb Function

    Time frame: 2 months

    Assessed by the Revised Upper Limb scale used to investigate the upper limb function of ambulatory and nonambulatory patients with Spinal Muscular Atrophy. The scale has 19 scorable items// Each item is scored from 0 to 2 0=Unable 1=Able, with modification 2=Able, no difficulty. The best possible final score is 0 and the worst final possible score is 38.

  2. Number of Steps

    Time frame: 2 months

    Changes in the physical performance with the exoskeleton of the children over time by assessing the number of steps. This data collected directly from the device information.

  3. Muscle Strength

    Time frame: 2 months

    Changes in muscle strength over time assessed by a hand held dynamometer at the begginig and at the end of the study. Every lower limb muscle is measured 3 times and the best result of the 3 is taken.

  4. Number of participants with abnormal vital signs

    Time frame: 2 months

    The data obtained in vital signs before and after using the exoskeleton will be analysed by comparing the data with the Pediatric Emergency Assessment Recognition and Stabilization (PEARS) Vital Signs form the American Heart Association. Any abnormal value will be registered.

  5. Respiratory rate (breaths/min)

    Time frame: 2 months

    The therapist took the respiratory rate by counting the number of breaths in one minute by observing the movement of the chest as the child breathed, before and after each session.

  6. Oxygen saturation

    Time frame: 2 months

    Oxygen saturation and heart rate were measured with a suitable pediatric pulse oximeter using the PC-900PRO® (Creative Medical®, Shenzen, China) before and after each session.

  7. Self percieved fatigue

    Time frame: 2 months

    Changes in self percieved fatigue before and after each session by using the OMNI (Omnibus) scale, a developmentally indexed category format that con- tains both pictorial and verbal descriptors positioned along a comparatively narrow numerical response range, i.e. category range 0 to 10. The best possible result is 0 and the worst is 10.

  8. Motor Function

    Time frame: 2 months

    Assessed by the Hammersmith Functional Motor Scale for Spinal Muscular Atrophy. Designed with a 3 point scoring system: Score 2 = performs without modification/adaptation/compensation Score 1 = performs with modification/adaptation/compensation Score 0 = unable to perform Specific scoring criteria per item is outlined in detail in this manual. The best possible final score is 0 and the worst final possible score is 99.

  9. Duration of time walking in each session.

    Time frame: 2 month

    Changes in the physical performance with the exoskeleton of the children over time by recording the duration of time walking in each session. This data collected directly from the device information.

  10. Blood pressure

    Time frame: 2 months

    Systolic and Diastolic blood pressure (mmHg). Using the PC-900PRO® (Creative Medical®, China) before and after each session.

    Blood pressure is taken with the child sitting, always using the same arm for each child, with the correct cuff size and with the arm at heart level.

  11. Social behaviour

    Time frame: 2 months

    Assessed by a semi-structured interview done to the child and the main care giver, and by participant observation which questions are focused on social behaviour aspects.

    No scales were used to assess the sense of agency.

  12. Exploration

    Time frame: 2 months

    Assessed by a semi-structured interview done to the child and the main care giver, and by particpant observation which questions are focused on exploration aspects. .

    Participant observation was performed during exoskeleton use sessions in the children's homes. Data was taken by field notes of everything that happened during the session and the analysis focused on exploration aspects.

    No scales were used to assess exploration.

  13. Sense of agency

    Time frame: 2 months

    Assessed by a semi-structured interview done to the child and the main care giver, and by participant observation which questions are focused on the sense of agency aspects.

    Participant observation was performed during exoskeleton use sessions in the children's homes. Data was taken by field notes of everything that happened during the session and the analysis focused on the sense of agency aspects.

    No scales were used to assess the sense of agency.

  14. Emotional impact

    Time frame: 2 months

    Assessed by a semi-structured interview done to the child and the main care giver which questions are focused on the emotional aspects, and by participant observation.

    Participant observation was performed during exoskeleton use sessions in the children's homes. Data was taken by field notes of everything that happened during the session and the analysis focused on emotional impact aspects.

    No scales were used to assess the emotional impact.

Sponsors and collaborators

Lead sponsor

MarsiBionics

Industry

Collaborators

  • Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Registry information

Official study title

Study of the Impact of a Gait Exoskeleton on the Quality of Life of Patients With Spinal Muscular Atrophy

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jun 13, 2022
Registry last updated
Jun 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.